BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fresenius Kabi AG Voluntarily Recalls One Lot of Magnesium Sulfate Injection


5/28/2013 7:21:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Fresenius Kabi USA Initiates Voluntary Recall of Single Lot of Magnesium Sulfate

LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi USA announced today it has initiated a voluntary recall of one lot – Lot 6103882 – of Magnesium Sulfate Injection, USP due to the potential presence of glass particles in the vials. The recall is a precautionary measure, following a routine company inspection of retained product samples.

No adverse events, patient reactions or customer complaints have been reported to date. All customers who received the recalled vials are being notified and instructed to return any unused product to their supplier.

The recalled product is labeled with Product Code 6450 and packaged as 500mg/mL strength in 50mL glass vials (25 vials per tray). The product was shipped in the United States between May 30, 2012 and June 6, 2012 and has an expiration date of October 31, 2014.

Magnesium sulfate is used as electrolyte replacement therapy in the treatment of magnesium deficiency, and as an anticonvulsant to prevent and control seizures in severe toxemia of pregnancy.

The administration of glass particulate, if present in a parenteral drug, poses a potential safety risk to patients. Case reports suggest that sequelae of thromboembolism, some life-threatening (such as pulmonary emboli), may occur. There have also been reports in the literature of particulate possibly causing phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli. Patients with preexisting condition of trauma or other medical condition that adversely affects the microvascular blood supply are at an increased risk. Administration of a glass particulate can also lead to formation of granulomas, which represent a protective local inflammatory response to the foreign material and are typically non-serious. The defect discovered in this product lot was noted as visible particulate.

To report adverse events or quality problems experienced with the use of this product, call Fresenius Kabi USA’s Vigilance and Medical Affairs at 1-800-551-7176, Monday through Friday, between the hours of 8 a.m. and 5 p.m. (CST), or by e-mail appmedicalinfo@APPpharma.com.

Adverse events may also be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

Online: www.fda.gov/medwatch/report.htm.

Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm.

Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787

Fax: 1-800-FDA-0178

Additional Fresenius Kabi contact information

Health care professionals can find additional information about the recall on the company’s web site (www.apppharma.com/our-products/product-updates) or by calling Fresenius Kabi USA Quality Assurance at 1-866-716-2459, Monday through Friday, between the hours of 8 a.m. and 5 p.m. (CST).

Questions regarding product availability and ordering can be directed to Fresenius Kabi USA Customer Service at 1-888-386-1300, Monday through Friday, between the hours of 7 a.m. and 6 p.m. (CST).

Fresenius Kabi USA is the U.S. subsidiary of Fresenius Kabi, a global health care company that focuses on medicines and medical devices used to care for critically and chronically ill patients inside and outside the hospital.

Contact:

Matt Kuhn

Fresenius Kabi

1-847-220-3033



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES